跳到正文
原文
@rohanpaul_ai· @rohanpaul_ai · X·· 2026-08-19精选AI 评分73
AI 导读

Anthropic 公布 Claude 自主设计 de novo 蛋白质结合体的实验结果:在 1320 个可测设计中 354 个结合目标,命中率 26.8%,15 个靶点中 14 个找到结合体。

推荐理由

论文给出 Claude 自主完成蛋白质设计全流程的可复现流程和实测命中率,便于评估智能体在科研实验中的实际边界。

正文

Anthropic published one of its most ambitious scientific experiments with Claude yet.

Anthropic showed that Claude can take a biological target and autonomously run the computational protein-design campaign needed to produce binders that actually work in the lab.

A lab may no longer need a dedicated protein-design expert to manually run every computational step. This can move the bottleneck from designing and triaging thousands of candidates toward experimentally testing a much smaller, AI-selected set

- Given a detailed expert-written protocol, it researched each target, chose where to bind, installed and ran open-source protein-design tools, generated candidates, filtered and improved them, then picked the final proteins for lab testing. Humans did not make the individual design decisions.

- The designs actually worked in the lab. Across 1,320 designs with usable measurements, 354 bound their intended targets, a 26.8% hit rate, and Claude found binders for 14 of 15 targets.

- On several targets, its results were competitive with human/open design competitions. Claude had higher hit rates on 4 of 6 comparable competition targets.

- Giving the agent more attention and compute seems to help. Mythos Preview reached a 35.1% hit rate when each target received its own 24-hour campaign, versus 26.7% when many targets shared a 48-hour campaign.

- The AI still cannot reliably know when a whole campaign has failed. Some unsuccessful targets received computational scores similar to successful ones.

引用@AnthropicAI@AnthropicAI
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
在 X 查看被引用的帖子

来源:@rohanpaul_ai · x.com